GeometryAgentsSystemsHuman BodyFULCRUM
Research
ArticlesThe ArticleEvidencePapersResearch Briefs
Tools
L7 Tools

Agent Database

258 therapeutic agents across 21 cancer types. Each agent is classified by sub-phase target, structural function, attack plane (hold/cross), and calibration quality.
258
Total agents
169
Calibrated from trial data
133
H Hold agents
125
C Cross agents
258 agents shown
Agent Cancer Op SP Function M Action Class Cal
5-FU + leucovorin Pancreatic adenocarcinoma H SP2 Miner 0.537 Transform Chemotherapy
5-FU/Capecitabine Gastric/GEJ H SP2 Architect 0.300 Transform Antimetabolite
5-FU/leucovorin Colorectal (metastatic) H SP2 Miner 0.593 Transform
5-Fluorouracil Head & Neck Squamous Cell (HNSCC) H SP2 Architect 0.450 Transform Antimetabolite
ADT (LHRH) Prostate (mCRPC) C SP1 Sentinel 0.500 Prevent Hormonal
Abemaciclib Breast HR+/HER2− H SP2 Architect 0.500 Transform CDK4/6 inhibitor
Abiraterone Prostate (mCRPC) C SP1 Sentinel 0.721 Prevent Novel hormonal
Acarbose Type 2 Diabetes H SP3 Sentinel 0.150 Alpha-glucosidase inhibition → delay glucose absorption Legacy
Adagrasib (KRAS G12C) Colorectal (metastatic) H SP2 Architect 0.560 Transform
Adagrasib (KRAS G12C) NSCLC (non-squamous) C SP1 Architect 0.600 Prevent
Aducanumab (discontinued) Alzheimer's Disease C SP1 Architect 0.150 Transform Anti-amyloid mAb
Alectinib NSCLC (non-squamous) H SP2 Architect 0.380 Transform Targeted (ALK)
Alpelisib Breast HR+/HER2− C SP3 Miner 0.490 Regain control PI3K inhibitor
Amikacin Tuberculosis H SP2 Miner 0.400 Ribosomal protein synthesis inhibition Group C
Amivantamab (EGFR exon20) NSCLC (non-squamous) C SP3 Catalyst 0.420 Regain control
Anastrozole Breast HR+/HER2− C SP1 Sentinel 0.558 Prevent Endocrine therapy
Apalutamide Prostate (mCRPC) H SP2 Sentinel 0.716 Transform Novel hormonal
Atezolizumab Hepatocellular Carcinoma (HCC) C SP3 Sentinel 0.350 Regain control ICI
Atezolizumab Melanoma C SP3 Sentinel 0.615 Regain control
Atezolizumab NSCLC (non-squamous) C SP3 Sentinel 0.575 Regain control Checkpoint inhibitor
Axitinib Renal cell carcinoma (clear cell) H SP2 Architect 0.563 Transform
Bedaquiline Tuberculosis C SP2 Catalyst 0.620 Inhibit ATP synthase Novel
Belzutifan Renal cell carcinoma (clear cell) H SP2 Architect 0.600 Transform
Belzutifan (HIF-2α) Renal cell carcinoma (clear cell) C SP1 Architect 0.580 Prevent
Bevacizumab Cervical Cancer H SP4 Observer 0.520 Slow Anti-angiogenic
Bevacizumab Colorectal (metastatic) H SP4 Sentinel 0.552 Slow
Bevacizumab Glioblastoma (GBM) C SP3 Sentinel 0.705 Regain control Anti-angiogenic
Bevacizumab Hepatocellular Carcinoma (HCC) H SP4 Observer 0.380 Slow Anti-angiogenic
Bevacizumab Melanoma H SP4 Sentinel 0.520 Slow
Bevacizumab NSCLC (non-squamous) H SP4 Sentinel 0.420 Slow Anti-angiogenic
Bevacizumab Ovarian (High-Grade Serous) H SP4 Observer 0.520 Slow Anti-angiogenic
Bevacizumab Triple-Negative Breast Cancer H SP4 Observer 0.450 Slow Anti-angiogenic
Binimetinib Melanoma H SP2 Architect 0.586 Transform Targeted therapy
Bisoprolol Heart Failure H SP2 Sentinel 0.420 Selective beta-1 blockade Pillar 2
Blood pressure optimisation Alzheimer's Disease H SP4 Miner 0.120 Consolidate Vascular
Broad-spectrum antibiotics Sepsis C SP1 Sentinel 0.550 Prevent Antimicrobial
Cabazitaxel Prostate (mCRPC) H SP4 Miner 0.683 Slow Chemotherapy
Cabozantinib Hepatocellular Carcinoma (HCC) H SP2 Architect 0.548 Transform TKI
Cabozantinib Prostate (mCRPC) H SP4 Sentinel 0.520 Slow
Cabozantinib Renal cell carcinoma (clear cell) H SP2 Sentinel 0.554 Transform
Canagliflozin Type 2 Diabetes C SP3 Observer 0.250 SGLT2 inhibition Preferred
Capecitabine Breast HR+/HER2− H SP2 Miner 0.580 Transform Chemotherapy
Capecitabine Colorectal (metastatic) H SP2 Miner 0.593 Transform
Carboplatin Breast HR+/HER2− H SP2 Miner 0.450 Transform
Carboplatin Endometrial Cancer C SP1 Miner 0.580 Prevent Platinum
Carboplatin NSCLC (non-squamous) H SP4 Miner 0.528 Slow Chemotherapy
Carboplatin Ovarian (High-Grade Serous) C SP1 Miner 0.620 Prevent Platinum
Carboplatin Triple-Negative Breast Cancer C SP1 Miner 0.580 Prevent Platinum
Carvedilol Heart Failure H SP2 Sentinel 0.440 Beta-1/2 + alpha-1 blockade Pillar 2
Cetuximab Head & Neck Squamous Cell (HNSCC) H SP4 Observer 0.550 Slow Targeted therapy
Cetuximab (KRAS WT) Colorectal (metastatic) C SP3 Sentinel 0.568 Regain control
Cisplatin Cervical Cancer C SP1 Miner 0.580 Prevent Platinum
Cisplatin Gastric/GEJ C SP1 Miner 0.340 Prevent Platinum
Cisplatin Head & Neck Squamous Cell (HNSCC) C SP1 Miner 0.600 Prevent Platinum
Cisplatin NSCLC (non-squamous) H SP4 Miner 0.520 Slow Chemotherapy
Cisplatin Ovarian (High-Grade Serous) C SP1 Miner 0.600 Prevent Platinum
Cisplatin Urothelial/Bladder Cancer C SP1 Miner 0.580 Prevent Platinum
Clofazimine Tuberculosis H SP3 Sentinel 0.320 Generate reactive oxygen species Group B
Cobimetinib Melanoma H SP2 Architect 0.580 Transform
Crizotinib NSCLC (non-squamous) H SP2 Architect 0.390 Transform
Crystalloid resuscitation (30mL/kg) Sepsis H SP2 Miner 0.400 Provoke Fluid
Cycloserine Tuberculosis H SP4 Sentinel 0.220 Inhibit cell wall peptidoglycan Group B
Dabrafenib Melanoma H SP2 Architect 0.673 Transform Targeted therapy
Dapagliflozin Heart Failure C SP4 Observer 0.380 SGLT2 inhibition → osmotic diuresis + metabolic shift Pillar 4
Dapagliflozin Type 2 Diabetes C SP3 Observer 0.270 SGLT2 inhibition → glycosuria Preferred
Darolutamide Prostate (mCRPC) H SP2 Sentinel 0.550 Transform Novel hormonal
Dato-DXd Breast HR+/HER2− C SP3 Catalyst 0.520 Catalyse
Dato-DXd NSCLC (non-squamous) C SP3 Catalyst 0.500 Catalyse
Delamanid Tuberculosis C SP1 Architect 0.460 Inhibit mycolic acid synthesis Novel
Digoxin Heart Failure H SP3 Sentinel 0.160 Na/K-ATPase inhibition → inotropy Legacy
Dobutamine Heart Failure C SP3 Catalyst 0.120 Beta-1 agonist → contractility Acute
Docetaxel Head & Neck Squamous Cell (HNSCC) H SP2 Architect 0.500 Transform Taxane
Docetaxel NSCLC (non-squamous) H SP2 Miner 0.350 Transform Chemotherapy
Docetaxel Prostate (mCRPC) H SP4 Miner 0.719 Slow Chemotherapy
Donanemab (Kisunla) Alzheimer's Disease C SP1 Architect 0.350 Transform Anti-amyloid mAb
Donepezil (Aricept) Alzheimer's Disease H SP3 Sentinel 0.250 Prevent Cholinesterase inhibitor
Dostarlimab Endometrial Cancer C SP3 Sentinel 0.650 Regain control Checkpoint inhibitor
Dulaglutide Type 2 Diabetes C SP1 Architect 0.420 GLP-1 receptor agonism Established
Durvalumab Hepatocellular Carcinoma (HCC) C SP3 Sentinel 0.420 Regain control ICI
Durvalumab NSCLC (non-squamous) C SP3 Sentinel 0.580 Regain control Checkpoint inhibitor
Early enteral nutrition Sepsis H SP4 Catalyst 0.200 Consolidate Supportive
Elacestrant Breast HR+/HER2− C SP1 Sentinel 0.590 Prevent
Empagliflozin Heart Failure C SP4 Observer 0.360 SGLT2 inhibition Pillar 4
Empagliflozin Type 2 Diabetes C SP3 Observer 0.270 SGLT2 inhibition Preferred
Enalapril Heart Failure H SP1 Sentinel 0.360 ACE inhibition Pillar 1 (legacy)
Encorafenib Melanoma H SP2 Architect 0.679 Transform Targeted therapy
Encorafenib (BRAF V600E) Colorectal (metastatic) H SP2 Architect 0.769 Transform
Enfortumab vedotin Urothelial/Bladder Cancer C SP3 Catalyst 0.721 Regain control ADC
Enzalutamide Prostate (mCRPC) H SP2 Sentinel 0.706 Transform Novel hormonal
Eplerenone Heart Failure C SP3 Architect 0.360 Selective MR antagonism Pillar 3
Erdafitinib Urothelial/Bladder Cancer H SP4 Observer 0.550 Slow Targeted therapy
Erlotinib Pancreatic adenocarcinoma C SP1 Architect 0.320 Prevent
Ertugliflozin Type 2 Diabetes C SP3 Observer 0.240 SGLT2 inhibition Established
Ethambutol Tuberculosis H SP2 Sentinel 0.250 Inhibit arabinosyltransferase First-line
Ethionamide Tuberculosis H SP1 Sentinel 0.250 Inhibit mycolic acid synthesis Second-line
Everolimus Breast HR+/HER2− H SP4 Miner 0.050 Slow mTOR inhibitor
Everolimus Hepatocellular Carcinoma (HCC) H SP4 Observer 0.200 Slow mTOR inhibitor
Everolimus Renal cell carcinoma (clear cell) H SP4 Miner 0.605 Slow
Everolimus Renal cell carcinoma (clear cell) H SP4 Miner 0.300 Slow
Exemestane Breast HR+/HER2− C SP1 Sentinel 0.570 Prevent Endocrine therapy
Exenatide (weekly) Type 2 Diabetes C SP1 Architect 0.360 GLP-1 receptor agonism Established
Finerenone Heart Failure C SP3 Architect 0.280 Nonsteroidal selective MR antagonism Novel
Fruquintinib Colorectal (metastatic) H SP4 Sentinel 0.530 Slow
Fulvestrant Breast HR+/HER2− C SP1 Sentinel 0.505 Prevent Endocrine therapy
Furosemide Heart Failure H SP4 Sentinel 0.150 Loop diuresis Symptomatic
Galantamine (Razadyne) Alzheimer's Disease H SP3 Sentinel 0.200 Prevent Cholinesterase inhibitor
Gemcitabine Ovarian (High-Grade Serous) H SP2 Miner 0.420 Transform Antimetabolite
Gemcitabine Pancreatic adenocarcinoma H SP2 Miner 0.537 Transform Chemotherapy
Gemcitabine Urothelial/Bladder Cancer H SP2 Architect 0.520 Transform Antimetabolite
Glimepiride Type 2 Diabetes H SP2 Miner 0.400 Stimulate insulin secretion Legacy
Glyburide Type 2 Diabetes H SP2 Miner 0.380 Stimulate insulin secretion Legacy
Hydralazine/Isosorbide Heart Failure H SP3 Sentinel 0.320 Direct vasodilation + NO donor Alternative
Hydrocortisone (200mg/d) Sepsis H SP3 Architect 0.350 Transform Corticosteroid
Hydrocortisone + Fludrocortisone Sepsis H SP3 Architect 0.420 Transform Corticosteroid combo
IFN-γ (immunostimulation) Sepsis C SP3 Catalyst 0.300 Catalyse Immunotherapy
IL-7 (lymphocyte recovery) Sepsis C SP3 Miner 0.280 Provoke Immunotherapy
Imlunestrant Breast HR+/HER2− C SP1 Sentinel 0.600 Prevent Endocrine therapy
Inavolisib Breast HR+/HER2− C SP3 Miner 0.590 Regain control PI3K inhibitor
Insulin aspart Type 2 Diabetes H SP4 Miner 0.350 Rapid-acting prandial insulin Essential
Insulin degludec Type 2 Diabetes H SP4 Sentinel 0.410 Ultra-long-acting insulin replacement Essential
Insulin glargine Type 2 Diabetes H SP4 Sentinel 0.430 Basal insulin replacement Essential
Insulin glargine U300 Type 2 Diabetes H SP4 Sentinel 0.440 Concentrated ultra-long-acting basal insulin Essential
Ipilimumab Hepatocellular Carcinoma (HCC) C SP3 Sentinel 0.360 Provoke ICI
Ipilimumab Melanoma C SP1 Sentinel 0.563 Provoke Checkpoint inhibitor
Ipilimumab NSCLC (non-squamous) C SP1 Sentinel 0.600 Provoke Checkpoint inhibitor
Ipilimumab Renal cell carcinoma (clear cell) C SP1 Sentinel 0.524 Provoke
Irinotecan Colorectal (metastatic) C SP1 Miner 0.598 Prevent
Irinotecan Pancreatic adenocarcinoma C SP1 Miner 0.529 Prevent Chemotherapy
Isoniazid Tuberculosis H SP1 Sentinel 0.580 Inhibit mycolic acid synthesis First-line
Ivabradine Heart Failure H SP2 Catalyst 0.200 If channel inhibition → heart rate reduction Add-on
Lecanemab (Leqembi) Alzheimer's Disease C SP1 Architect 0.270 Transform Anti-amyloid mAb
Lenvatinib Endometrial Cancer H SP4 Observer 0.745 Slow Anti-angiogenic TKI
Lenvatinib Hepatocellular Carcinoma (HCC) C SP1 Sentinel 0.430 Prevent TKI
Lenvatinib Melanoma H SP4 Sentinel 0.580 Slow
Lenvatinib Renal cell carcinoma (clear cell) H SP2 Sentinel 0.597 Transform
Letrozole Breast HR+/HER2− C SP1 Sentinel 0.615 Prevent Endocrine therapy
Levofloxacin Tuberculosis C SP3 Architect 0.440 Block DNA gyrase Group A
Linagliptin Type 2 Diabetes H SP1 Sentinel 0.200 DPP-4 inhibition Established
Linezolid Tuberculosis H SP4 Miner 0.480 Block protein synthesis Group A
Liraglutide Type 2 Diabetes C SP1 Architect 0.450 GLP-1 receptor agonism Established
Lithium (microdose) Alzheimer's Disease H SP2 Miner 0.150 Slow GSK-3β inhibitor
Lomustine Glioblastoma (GBM) H SP2 Architect 0.676 Transform Alkylating
Lorlatinib NSCLC (non-squamous) H SP2 Architect 0.370 Transform
Lorlatinib (ALK+) NSCLC (non-squamous) C SP1 Architect 0.660 Prevent
Lu-PSMA-617 Prostate (mCRPC) C SP3 Catalyst 0.930 Catalyse Radioligand
Masitinib (experimental) Alzheimer's Disease C SP3 Catalyst 0.220 Catalyse Anti-inflammatory
Memantine (Namenda) Alzheimer's Disease H SP4 Sentinel 0.200 Slow NMDA antagonist
Metformin Type 2 Diabetes H SP2 Sentinel 0.380 Suppress hepatic glucose + improve insulin sensitivity Foundation
Metoprolol succinate Heart Failure H SP2 Sentinel 0.400 Selective beta-1 blockade Pillar 2
Milrinone Heart Failure C SP3 Catalyst 0.100 PDE3 inhibition → inotropy + vasodilation Acute
Mirvetuximab soravtansine Ovarian (High-Grade Serous) C SP3 Catalyst 0.550 Regain control ADC
Moxifloxacin Tuberculosis C SP3 Architect 0.500 Block DNA gyrase Group A
Nab-paclitaxel Pancreatic adenocarcinoma H SP4 Miner 0.539 Slow Chemotherapy
Nal-Irinotecan Pancreatic adenocarcinoma H SP2 Miner 0.520 Transform
Nal-irinotecan Pancreatic adenocarcinoma C SP1 Miner 0.540 Prevent
Niraparib Ovarian (High-Grade Serous) C SP3 Sentinel 0.580 Regain control PARPi
Niraparib (HRR+) Prostate (mCRPC) H SP2 Miner 0.560 Transform
Nitroglycerin Heart Failure H SP3 Sentinel 0.100 Venodilation → preload reduction Acute
Nivolumab Gastric/GEJ C SP3 Sentinel 0.270 Regain control Checkpoint inhibitor
Nivolumab Head & Neck Squamous Cell (HNSCC) C SP3 Sentinel 0.753 Regain control Checkpoint inhibitor
Nivolumab Hepatocellular Carcinoma (HCC) C SP3 Sentinel 0.460 Regain control ICI
Nivolumab Melanoma C SP3 Sentinel 0.641 Regain control Checkpoint inhibitor
Nivolumab NSCLC (non-squamous) C SP3 Sentinel 0.580 Regain control Checkpoint inhibitor
Nivolumab Renal cell carcinoma (clear cell) C SP3 Sentinel 0.460 Regain control
Nivolumab (MSI-H) Colorectal (metastatic) C SP3 Sentinel 0.580 Regain control
Norepinephrine Sepsis H SP2 Sentinel 0.500 Prevent Vasopressor
Olaparib Ovarian (High-Grade Serous) C SP3 Sentinel 0.720 Regain control PARPi
Olaparib Pancreatic adenocarcinoma H SP4 Miner 0.569 Slow Targeted therapy
Olaparib Prostate (mCRPC) C SP3 Miner 0.620 Regain control Targeted therapy
Olaparib Triple-Negative Breast Cancer C SP3 Sentinel 0.550 Regain control PARPi
Olaparib (BRCA+) Pancreatic adenocarcinoma H SP2 Miner 0.580 Transform
Omecamtiv mecarbil Heart Failure H SP4 Catalyst 0.140 Cardiac myosin activator Novel
Osimertinib NSCLC (non-squamous) H SP2 Architect 0.400 Transform Targeted (EGFR)
Oxaliplatin Colorectal (metastatic) H SP4 Miner 0.603 Slow
Oxaliplatin Gastric/GEJ C SP1 Miner 0.390 Prevent Platinum
Oxaliplatin Pancreatic adenocarcinoma C SP3 Miner 0.529 Regain control Chemotherapy
PEG Liposomal Doxorubicin Ovarian (High-Grade Serous) H SP2 Architect 0.480 Transform Anthracycline
Paclitaxel Cervical Cancer H SP2 Architect 0.520 Transform Taxane
Paclitaxel Endometrial Cancer H SP2 Architect 0.520 Transform Taxane
Paclitaxel Gastric/GEJ H SP2 Architect 0.480 Transform Taxane
Paclitaxel NSCLC (non-squamous) H SP2 Miner 0.540 Transform Chemotherapy
Paclitaxel Ovarian (High-Grade Serous) H SP2 Architect 0.580 Transform Taxane
Paclitaxel (nab) Triple-Negative Breast Cancer H SP2 Architect 0.550 Transform Taxane
Palbociclib Breast HR+/HER2− H SP2 Architect 0.350 Transform CDK4/6 inhibitor
Panitumumab (KRAS WT) Colorectal (metastatic) C SP3 Sentinel 0.568 Regain control
Para-aminosalicylic acid Tuberculosis H SP1 Sentinel 0.180 Folate synthesis inhibition Group C
Pembrolizumab Breast HR+/HER2− C SP3 Sentinel 0.380 Regain control
Pembrolizumab Cervical Cancer C SP3 Sentinel 0.620 Regain control Checkpoint inhibitor
Pembrolizumab Endometrial Cancer C SP3 Sentinel 0.600 Regain control Checkpoint inhibitor
Pembrolizumab Head & Neck Squamous Cell (HNSCC) C SP3 Sentinel 0.580 Regain control Checkpoint inhibitor
Pembrolizumab Hepatocellular Carcinoma (HCC) C SP3 Sentinel 0.583 Regain control ICI
Pembrolizumab Melanoma C SP3 Sentinel 0.621 Regain control Checkpoint inhibitor
Pembrolizumab NSCLC (non-squamous) C SP3 Sentinel 0.570 Regain control Checkpoint inhibitor
Pembrolizumab Ovarian (High-Grade Serous) C SP3 Sentinel 0.350 Regain control Checkpoint inhibitor
Pembrolizumab Renal cell carcinoma (clear cell) C SP3 Sentinel 0.460 Regain control
Pembrolizumab Triple-Negative Breast Cancer C SP3 Sentinel 0.600 Regain control Checkpoint inhibitor
Pembrolizumab Urothelial/Bladder Cancer C SP3 Sentinel 0.678 Regain control Checkpoint inhibitor
Pembrolizumab (MSI-H only) Colorectal (metastatic) C SP3 Sentinel 0.659 Regain control
Pembrolizumab (MSI-H) Pancreatic adenocarcinoma C SP3 Sentinel 0.550 Regain control
Pembrolizumab (MSI-H) Prostate (mCRPC) C SP3 Sentinel 0.480 Regain control
Pemetrexed NSCLC (non-squamous) H SP2 Miner 0.520 Transform Chemotherapy
Pioglitazone Type 2 Diabetes C SP2 Architect 0.280 PPAR-gamma agonism Legacy
Pretomanid Tuberculosis C SP4 Catalyst 0.540 Inhibit mycolic acid + anaerobic respiration Novel
Protective ventilation (lung-protective) Sepsis H SP4 Sentinel 0.350 Slow Organ support
Pyrazinamide Tuberculosis C SP4 Observer 0.550 Disrupt membrane energetics at acid pH First-line
Radium-223 Prostate (mCRPC) H SP4 Miner 0.660 Slow
Radium-223 Prostate (mCRPC) H SP4 Miner 0.550 Slow
Ramucirumab Gastric/GEJ H SP4 Observer 0.250 Slow Anti-angiogenic
Ramucirumab Hepatocellular Carcinoma (HCC) H SP4 Observer 0.551 Slow Anti-angiogenic
Ramucirumab NSCLC (non-squamous) H SP4 Sentinel 0.380 Slow
Regorafenib Colorectal (metastatic) H SP2 Sentinel 0.836 Transform
Regorafenib Hepatocellular Carcinoma (HCC) H SP2 Architect 0.565 Transform TKI
Renal replacement therapy Sepsis H SP4 Miner 0.250 Consolidate Organ support
Ribociclib Breast HR+/HER2− H SP2 Architect 0.500 Transform CDK4/6 inhibitor
Rifampin Tuberculosis H SP2 Miner 0.720 Block RNA polymerase First-line
Rifapentine Tuberculosis H SP2 Miner 0.680 Block RNA polymerase First-line
Rivastigmine (Exelon) Alzheimer's Disease H SP3 Sentinel 0.220 Prevent Cholinesterase inhibitor
Rucaparib Ovarian (High-Grade Serous) C SP3 Sentinel 0.650 Regain control PARPi
Sacituzumab govitecan Breast HR+/HER2− C SP3 Catalyst 0.530 Catalyse
Sacituzumab govitecan Triple-Negative Breast Cancer C SP3 Catalyst 0.428 Regain control ADC
Sacubitril/Valsartan Heart Failure C SP1 Architect 0.480 Neprilysin + AT1 receptor dual blockade Pillar 1
Savolitinib Renal cell carcinoma (clear cell) H SP2 Architect 0.550 Transform
Semaglutide Heart Failure C SP4 Architect 0.220 GLP-1 RA → weight loss + metabolic improvement Novel
Semaglutide (injectable) Type 2 Diabetes C SP1 Architect 0.520 GLP-1 receptor agonism Preferred
Semaglutide (oral) Type 2 Diabetes C SP1 Architect 0.450 Oral GLP-1 receptor agonism Novel
Semorinemab (anti-tau) Alzheimer's Disease H SP2 Sentinel 0.080 Prevent Anti-tau mAb
Sitagliptin Type 2 Diabetes H SP1 Sentinel 0.220 DPP-4 inhibition Established
Sorafenib Hepatocellular Carcinoma (HCC) C SP1 Sentinel 0.350 Prevent TKI
Sotorasib NSCLC (non-squamous) H SP2 Architect 0.370 Transform Targeted (KRAS)
Sotorasib (KRAS G12C) Colorectal (metastatic) H SP2 Architect 0.560 Transform
Source control (surgical/drainage) Sepsis C SP1 Architect 0.450 Transform Surgical
Spartalizumab Melanoma C SP3 Sentinel 0.520 Regain control
Spironolactone Heart Failure C SP3 Architect 0.400 Mineralocorticoid receptor antagonism Pillar 3
Streptomycin Tuberculosis H SP2 Miner 0.380 Ribosomal protein synthesis inhibition Historical
Structured aerobic exercise Alzheimer's Disease C SP4 Catalyst 0.150 Consolidate Lifestyle
Sunitinib Renal cell carcinoma (clear cell) H SP2 Architect 0.538 Transform
T-DXd (HER2-low) Breast HR+/HER2− C SP3 Catalyst 0.520 Catalyse ADC
T-VEC Melanoma C SP1 Catalyst 0.550 Provoke Oncolytic
TAS-102 Colorectal (metastatic) H SP2 Miner 0.280 Transform
TAS-102 (Lonsurf) Colorectal (metastatic) H SP2 Miner 0.280 Transform
TTFields Glioblastoma (GBM) H SP4 Observer 0.480 Slow Device
Tamoxifen Breast HR+/HER2− C SP1 Sentinel 0.585 Prevent Endocrine therapy
Tebentafusp Melanoma C SP1 Catalyst 0.550 Provoke
Temozolomide Glioblastoma (GBM) C SP1 Miner 0.550 Prevent Alkylating
Temozolomide Melanoma H SP2 Miner 0.420 Transform
Tiragolumab (anti-TIGIT) NSCLC (non-squamous) C SP1 Sentinel 0.540 Provoke
Tirzepatide Type 2 Diabetes C SP1 Catalyst 0.650 Dual GIP + GLP-1 receptor agonism Novel
Tivozanib Renal cell carcinoma (clear cell) H SP2 Sentinel 0.449 Transform
Trametinib Melanoma H SP2 Architect 0.591 Transform Targeted therapy
Trastuzumab Gastric/GEJ C SP3 Catalyst 0.330 Regain control Targeted therapy
Tremelimumab Hepatocellular Carcinoma (HCC) C SP3 Sentinel 0.280 Provoke ICI
Tremelimumab NSCLC (non-squamous) C SP1 Sentinel 0.560 Provoke
Tucatinib Breast HR+/HER2− C SP1 Architect 0.550 Prevent
Tucatinib (HER2+) Colorectal (metastatic) C SP3 Architect 0.570 Regain control
Valsartan Heart Failure H SP1 Sentinel 0.300 AT1 receptor blockade Pillar 1 (alt)
Vasopressin (add-on) Sepsis H SP2 Catalyst 0.250 Accelerate Vasopressor
Vericiguat Heart Failure C SP3 Catalyst 0.180 Soluble guanylate cyclase stimulation Novel
iGlarLixi (Soliqua) Type 2 Diabetes C SP4 Architect 0.520 Fixed-ratio insulin + GLP-1 RA Combination